Asafoetida

Other Names

A-weiAgudagandhuAngajahAngojAngozaAngozadAngustha-GandhaAnguzeAngzooAnjadanAnksarAsafetidaAsantAssa-foetidaBadharaniBadhikaBahleekaDevil's dungFerula alliaceaFerula asafoetidaFerula assa-foetidaFerula erubescensFerula foetidaFerula narthexFerula pseudalliaceaFerula rubricaulisFood of the godsHaltheethHaltitHeengHenguHilteelHiltitHingHingaHingraHinguHingukaInguIngumoInguraInguvaIrani HingJantughnaJatukaKaayamKamaKayamNuhurtuPerumkayamPerungayamRamathaResina FerulaeSahasravedhiSapSheinghoSimagh-ul-mehroosStinking gumTingTyibUgragandhaXingyuYangZallouh形虞阿魏

Synopsis

Asafoetida (Ferula assa-foetida L.): A Comprehensive Reference

1. Identity: Botanical Names, Natural Source, and Common Forms

1.1 Botanical Classification and Nomenclature

Asafoetida is the dried latex (gum oleoresin) exuded from the rhizome or tap root of several species of Ferula, perennial herbs of the carrot family (Apiaceae). In the system of biological nomenclature established in the mid-18th century by Carl Linnaeus, the plant identified as producing asafoetida was assigned the binomial name Ferula assa-foetida.

The resin is most commonly associated with Ferula assa-foetida and Ferula foetida, which were long treated as synonyms. Ferula narthex is also frequently cited as a source. Additional Ferula species are mentioned in the specialised literature, although they appear to be of lesser economic importance and may differ substantially in their phytochemical composition. Ferula foetida is native to Central Asia (Kyzylkum Desert, Karakum Desert, Turkmenistan), Eastern Iran, western Afghanistan, and western Pakistan, and is the most widely distributed species that produces asafoetida.

The Latin name ferula means "carrier" or "vehicle." Asa is a Latinized form of the Farsi word for "resin," and the Latin foetidus means "smelling, fetid."

1.2 Plant Description and Geographical Origin

Ferula asafoetida is an herbaceous, monoecious, perennial plant of the Umbelliferae family. Asafoetida is native to central Asia, eastern Iran to Afghanistan, and today it is grown chiefly in Iran and Afghanistan, from where it is exported to the rest of the world. It is produced in Iran, Afghanistan, India, Central Asia, and north-western China (Xinjiang).

This species grows to heights of 2 to 3 meters, featuring a stout stem, large pinnate leaves, and yellow umbelliferous flowers that bloom in the fourth or fifth year of growth. Ferula assa-foetida is native to arid and semi-arid mountainous habitats in eastern Iran and Afghanistan, where it develops massive taproots up to 15 cm in diameter after several years. These plants exhibit a monocarpic growth cycle, flowering once before dying, and are perennial in their natural environments.

Most of the asafoetida (heeng) is commercially sourced from this unique Iranian medicinal plant species through oleo-gum-resin (OGR) extracted from its fleshy taproots. All over the world, India consumes a huge amount of heeng, but it is not cultivated in India. Therefore, all the requirement of asafoetida (heeng) is met through imports from other countries. India consumes about 40% of the total production of F. assa-foetida.

1.3 Extraction and Common Preparations

Asafoetida is extracted from the Ferula plants, which have massive taproots or carrot-shaped roots, 12.5–15 cm in diameter at the crown when they are 4–5 years old. Just before the plants flower, in March–April, the upper part of the living rhizome root is laid bare and the stem cut off close to the crown. Harvesting involves cutting the root near the base; a milky latex oozes out and hardens over several days, and the process repeats throughout the season. The hardened resin is then ground and blended with wheat flour or rice flour to create the asafetida powder sold in shops. Pure resin exists too, but the powder is easier to measure and more widely available.

Common commercial forms include:

Raw oleo-gum-resin (lump form): The unprocessed dried exudate, yellowish-brown in color, used in traditional medicine.
Compounded powder: The hardened resin ground and blended with wheat flour or rice flour.
Encapsulated food-grade extract: Standardized formulations used in clinical research, such as the "Asafin" preparation evaluated in human trials.
Tinctures and hydroalcoholic extracts: Used in traditional and modern herbal medicine.

The chemical composition of asafoetida is influenced by factors such as harvesting dates, collection time of oleo-gum-resin, temperature, soil properties, and geographical location.

1.4 Common Names and Synonyms

Other names include: Anghuzeh (Farsi); asafétida (Spanish); awei (Chinese); aza (Greek); devil's dung; férule persique or merde du diable (French); haltit or tyib (Arabic); hing (Hindi); mvuje (Swahili); stinkasant or Teufelsdreck (German); stinking gum.

2. Traditional and Historical Use

2.1 Ancient and Early Historical Records

Asafoetida is frequently mentioned in Ayurvedic texts, later in Arabo-Persian medical treatises, in medieval herbals, in the literature of traditional Chinese medicine, and in the pharmacopoeias of the early modern period. Some authors have proposed that asafoetida was already included in ancient pharmacopoeias and may be identifiable in some of the earliest medical texts. It has been suggested, for example, that it is mentioned in the Ebers Papyrus, an Egyptian medical treatise dating to the 16th century BCE, where it appears in treatments for severe burns and in ophthalmic collyriums administered with a vulture feather. The resin may also have been among the medicinal plants known and cultivated in Mesopotamia.

Hilteet is an oleo-gum-resin obtained from the rhizomes and roots of Ferula asafoetida and related species. It has a long history of medicinal use, first documented by Theophrastus and Dioscorides, and is frequently employed in Unani medicine.

In ancient Rome, asafoetida was stored in jars together with pine nuts, which were alone used to flavor delicate dishes. While asafoetida was embraced in many cultures, its strong sulfurous odor earned it the unflattering nickname "Devil's Dung" in medieval Europe.

2.2 Ayurvedic Tradition

Dating back to antiquity, asafoetida or hingu has played an integral role in Ayurveda and finds its mention in revered classical texts like the Charaka Samhita and Sushruta Samhita. Traditionally, it is prescribed as a therapeutic remedy for a wide array of ailments, including digestive disorders, respiratory problems, and even as a rejuvenative tonic for restoring good health.

This herb is the major component in the famous Ayurvedic herbal formula Hingashtak, Sanskrit name hing. Its taste is pungent, its energy is hot, and its post-digestive effect (vipaka) is also pungent. In Ayurvedic terms, this means it reduces Vata and Kapha, both of which are cold and heavy by nature, while it aggravates Pitta, the fiery dosha.

In traditional Ayurvedic systems, it is specially considered an ailment for women, used as a treatment for problems such as unwanted abortion, unusual pain, sterility, difficult and excessive menstruation, and leucorrhoea.

2.3 Persian and Middle Eastern Traditions

In Persia, asafoetida was used as a condiment and called the "food of the gods." Celebrated in ancient Persian texts as a food of the gods, asafoetida has historically been revered for its potent aroma and therapeutic applications, particularly in digestive and inflammatory disorders.

2.4 Uses in Western and Unani Traditions

This spice is used as a digestive aid, in food as a condiment, and in pickles. It is used in modern herbalism in the treatment of hysteria, some nervous conditions, bronchitis, asthma, and whooping cough. It was at one time employed in the treatment of infantile pneumonia and flatulent colic. The gum resin is antispasmodic, carminative, expectorant, laxative, and sedative.

The volatile oil in the gum is eliminated through the lungs, making it an historical treatment for asthma. In traditional medical systems, including Ayurveda, Unani medicine, and Western phytotherapy, asafoetida has been used for a variety of purposes, particularly in relation to the gastrointestinal and respiratory systems.

3. Key Constituents and Active Compounds

3.1 Gross Composition of the Oleo-Gum-Resin

There is a large amount of resin (about 60%) and about 20% gum, and from 4 to 5% of essential oil in the raw material. In some tear (exudate) samples, the essential oil content is up to 15%.

3.2 Volatile Organosulfur Compounds

The volatile oil component is rich in various organosulfide compounds, such as 2-butyl-propenyl-disulphide, diallyl sulphide, diallyl disulphide (also present in garlic), and dimethyl trisulfide, which is also responsible for the odour of cooked onions. The organosulfides are primarily responsible for the odour and flavour of asafoetida.

The major sulphur-containing compounds — 2-butyl (E,Z)-1-propenyl disulfide, 1-(methylthio)propyl (E,Z)-1-propenyl disulfide, and 2-butyl 3-(methylthio)-2-propenyl disulfide — have been identified in Ferula asafoetida. From a pharmacological perspective, organosulfur compounds have been reported to exhibit anti-inflammatory, immunomodulatory, antihypertensive, antioxidant, and hypocholesterolaemic activities.

3.3 Sesquiterpene Coumarins

A comprehensive review by Iranshahy and Iranshahi (2011) covered coumarins and sesquiterpene coumarins, sulfur-containing compounds, diterpenes, phenolics, sesquiterpenes, and other miscellaneous compounds in Ferula asafoetida oleo-gum-resin. Additional cyclic derivatives of sesquiterpene coumarins — including gummosin, assafoetidnol A and B, polyanthine, badrakemin, samarcandin, feselol, microlobidene, and kellerin — have been identified in asafoetida and other Ferula species, and several of these compounds continue to be the subject of pharmacological research.

3.4 Ferulic Acid and Other Phenolic Compounds

Ferulic acid is a phenolic derivative of cinnamic acid that is widespread and abundant in the plant cell wall. Umbelliprenin and ferulic acid are the major phenolic compounds found in both leaf and gum extracts of F. asafoetida. Seven phenolic compounds have been identified in both leaf and gum extracts, including ferulic acid, vanillic acid, coumaric acid, umbelliprenin, galbanic acid, karatavicinol, and kamolonol.

Ferulic acid, a potent antioxidant, functions by scavenging free radicals and enhancing the body's endogenous antioxidant defense systems.

3.5 Gum Fraction

Asafoetida also contains gum arabic, a water-soluble polysaccharide. The gum fraction provides the water-solubility properties of the oleo-gum-resin and contributes to its physical consistency.

3.6 Umbelliprenin

Studies conducted recently have revealed the promising activity of umbelliprenin in the inhibition of inflammation, carcinogenesis, genotoxicity, lipoxygenase, and acetylcholinesterase, also demonstrating its cytotoxic features. Umbelliprenin, in particular, has been observed to inhibit lipoxygenase, thereby reducing the synthesis of pro-inflammatory mediators.

4. Established and Proposed Mechanisms of Action

4.1 Anti-inflammatory Pathways

Asafoetida exhibits potent anti-inflammatory activity by suppressing key mediators like tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), and cyclooxygenase-2 (COX-2). Phenolic constituents including ferulic acid and umbelliprenin contribute to anti-inflammatory action primarily through suppression of nuclear factor kappa-B (NF-κB) transcriptional activity, thereby reducing downstream expression of cyclooxygenase-2 and pro-inflammatory cytokines such as TNF-α and IL-6 in cell-based models.

4.2 Antioxidant Mechanisms

Antioxidant activity is mediated by hydrogen-atom transfer and single-electron transfer mechanisms from the phenolic hydroxyl groups of ferulic acid, coumaric acid, and flavonoid constituents, quenching reactive oxygen species. The phytochemicals ferulic acid, umbelliprenin, and asaresinotannols help defend against oxidative stress.

4.3 Antispasmodic and Smooth Muscle Relaxant Effects

The resin and volatile oils of asafoetida are believed to synergize to produce its antispasmodic effect, easing digestive tract spasms and mitigating gastrointestinal distress. The anti-flatulent effects of asafoetida are attributed to reduced gas formation in the intestines and increased expulsion of trapped gas. According to a recent meta-analysis, asafoetida relaxes intestinal smooth muscles, which may relieve cramping and abdominal pain, especially in individuals with irritable bowel syndrome (IBS).

4.4 Digestive Enzyme Stimulation

Asafoetida plays an important role in the digestion of dietary lipids by stimulating bile flow, enhancing bile acid secretion, and also enhancing the activities of digestive enzymes of the pancreas and small intestine. Moreover, it is used for low acid levels in the stomach, stomach pressure, flatulence, and loose stools.

4.5 Antihypertensive Mechanisms

A part of the antihypertensive effect of asafoetida is mediated through inhibition of the angiotensin II type 1 receptor. This was demonstrated in a preclinical (animal) study; no clinical trials on this mechanism have been identified.

4.6 Antidiabetic Mechanisms

The possible mechanisms of the antidiabetic effect of asafoetida include potentiating insulin release at lower doses of the extract, preventing intestinal α-glucosidase, and activating glucokinase. All reported antidiabetic mechanistic work to date is from animal models.

4.7 Neuroprotective Mechanisms

Asafoetida (ASF), an oleo-gum-resin isolated from Ferula assa-foetida root, has been proven to possess antioxidative potential and neuroprotective effects, which are closely associated with neurological disorders. A 2022 study published in Chinese Medicine evaluated these effects through the PI3K/Akt/GSK3β/Nrf2/HO-1 pathway in both a mouse scopolamine-induced cognitive impairment model and H₂O₂-stimulated PC12 cells, providing preclinical mechanistic evidence.

4.8 Antimicrobial Mechanisms

F. asafoetida has broad-spectrum antibacterial activity because it showed potential inhibitory effects against tested strains of bacteria. Bioactive substances from this plant can therefore be worked into the formulation of antibacterial agents for the treatment of various bacterial infections mainly related to the digestive system.

5. Scientific Evidence by Area of Use

5.1 Functional Dyspepsia

Evidence Level: Preliminary human clinical data, small sample sizes, limited replication.

The most directly relevant human clinical trial examined asafoetida in functional dyspepsia (FD). In this double-blinded, placebo-controlled study, 43 subjects diagnosed with moderate to severe discomforts of nonulcer FD were randomized to receive hard-shell capsules (250 mg × 2/day) of either placebo (n=22) or a food-grade formulation of asafoetida (Asafin) (n=21) for 30 days. When evaluated by a set of validated indexing tools (GSRS, GDSS, and NDI), almost 81% in the Asafin group showed significant (p < 0.01) improvement in the overall score and quality of life as compared to the placebo. At the end of the study, 66% of subjects in the Asafin group remained symptoms-free.

The relative percentage of subjects in the Asafin group with more than 80% reduction in various symptoms were: bloating (58%), appetite (69%), postprandial fullness (74%), motion sickness (75%), and digestion (77%), as compared to less than 10% nonspecific improvement in the placebo group.

A second randomized, double-blind, placebo-controlled trial, published in 2025 in Medicine (Baltimore) and registered in the Clinical Trial Registry of India (CTRI/2022/07/044075), further investigated the effect of Ferula asafoetida oleo-gum resin on dyspepsia symptoms, including through modulation of the microbiome-gut-brain axis in adults aged 18–75 with mild to moderate FD symptoms.

Although preclinical studies and traditional use highlight the therapeutic potential of asafoetida, robust clinical evidence remains limited to preliminary studies often conducted on small sample sizes with variable methodologies. Larger and well-controlled human trials are required to elucidate the efficacy of asafoetida for the management of digestive and inflammatory conditions.

5.2 Irritable Bowel Syndrome (IBS)

Evidence Level: Very low quality; derived from small homeopathic trials with high risk of bias.

A pooled analysis of two small studies suggests a possible benefit for clinical homeopathy, using the remedy asafoetida, over placebo for people with constipation-predominant IBS. These results should be interpreted with caution due to the low quality of reporting in these trials, high or unknown risk of bias, short-term follow-up, and sparse data.

A meta-analysis of two small studies (129 participants with constipation-predominant IBS) found a statistically significant difference in global improvement between the homeopathic remedy asafoetida and placebo at a short-term follow-up of two weeks. Seventy-three percent of patients in the homeopathy group improved compared to 45% of placebo patients (RR 1.61, 95% CI 1.18 to 2.18). There was no statistically significant difference in global improvement between the homeopathic remedies asafoetida plus nux vomica and placebo. Sixty-eight percent of patients in the homeopathy group improved compared to 52% of placebo patients (1 study, N=42, RR 1.31, 95% CI 0.80 to 2.15). GRADE analyses rated the overall quality of the evidence for the outcome global improvement as very low due to high or unknown risk of bias, short-term follow-up, and sparse data.

It bears emphasis that the IBS trials described above used homeopathic preparations, not pharmacological or botanical-dose asafoetida; the evidence cannot be straightforwardly extrapolated to supplement-dose use.

5.3 Antimicrobial Activity

Evidence Level: In vitro and preclinical only; no human clinical trials.

The antibacterial and antifungal activity of chloroform, ethyl acetate, ethanol, methanol, and aqueous extracts of asafoetida were studied against B. subtilis, E. coli, Klebsiella pneumoniae, S. aureus, A. niger, and Candida albicans. Ethyl acetate, ethanol, and methanol extracts showed significant antimicrobial activity, and the plant could be a source of new antibiotic compounds. These findings are in vitro only.

5.4 Antihypertensive Effects

Evidence Level: Preclinical (animal) only; no human clinical trials.

Results of one animal study indicated that aqueous extract of asafoetida ameliorated cardiovascular responses in acute hypertension induced by angiotensin II. This effect at a lower dose was more effective and comparable with losartan. All antihypertensive evidence is from animal models; no human cardiovascular trials have been published.

5.5 Antidiabetic Effects

Evidence Level: Preclinical (animal and in vitro) only; no human clinical trials.

Asafoetida extract had an antidiabetic effect both on alloxan and streptozotocin diabetic rats. The aqueous extract significantly reduced blood glucose and increased insulin level in alloxan diabetic rats. The possible mechanisms included potentiating insulin release at lower doses of the extract, preventing intestinal α-glucosidase, and activating glucokinase.

5.6 Anticancer Activity

Evidence Level: In vitro and preclinical only; no human clinical trials.

Isolation of galbanic acid, karatavicinol, umbelliprenin, farnesiferol B, and farnesiferol C from Ferula assa-foetida to inhibit farnesyltransferase (FTase) showed that galbanic acid has the highest enzyme inhibition potential, with an IC50 calculated as 2.5 μM. The calculated IC50 value in reducing the proliferation of oncogenic ras-transformed NIH3T3/Hras-F cells by galbanic acid was 16.2 μM compared to the control group.

Ferula assa-foetida ethanolic extract showed a significant effect on PC12 and MCF7 cells in reducing cell survival. The IC50 values for 24, 48, and 72 hours for MCF7 cells were 1.30, 1.284, and 0.753 μM, respectively. IC50s for PC12 at 24, 48, and 72 hours were 2.84, 0.8, and 0.4 μM, respectively. These are cell-line (in vitro) findings only.

5.7 Neuroprotective Effects

Evidence Level: Preclinical (animal and in vitro); no human clinical trials.

Asafoetida has been shown to possess antioxidative potential and neuroprotective effects closely associated with neurological disorders. However, the efficacy and further mechanisms of asafoetida in Alzheimer's disease experimental models are still under investigation. All current neuroprotective evidence derives from rodent and cell-line models.

5.8 Antioxidant Activity

Evidence Level: In vitro; no human clinical trials specifically for antioxidant endpoints.

Leaf extract of Ferula asafoetida contained greater phenolic and flavonoid compounds and thus higher DPPH scavenging and ferric reducing power than gum extract in hydroalcoholic extract studies. FA's active constituents, known for their potent antioxidant and anti-inflammatory activities, may counteract oxidative stress and cellular damage.

5.9 Respiratory Conditions

Evidence Level: Traditional use only; no controlled human trials.

Asafoetida is used in modern herbalism in the treatment of hysteria, some nervous conditions, bronchitis, asthma, and whooping cough. The traditional rationale is that the volatile oil in the gum is eliminated through the lungs. No controlled clinical trials in human respiratory populations have been published.

5.10 Summary of Evidence Quality

In the 1990s, pharmacopoeias noted that the medicinal use of asafoetida was not supported by clinical evidence. During the first two decades of the 21st century, a substantial body of pharmacological research, mainly conducted in Iran, examined the properties of the oleo-gum-resin. These studies, primarily based on laboratory and preclinical models, have reported a range of biological activities that suggest pharmacological potential. The specific active phytochemical constituents have not yet been fully identified, and further investigation is required to establish their safety and clinical relevance.

6. Body Systems and Health Areas of Association

Recent studies of pharmacological and biological activities have shown that asafoetida possesses numerous activities such as a relaxant, neuroprotective, memory enhancing, digestive enzyme stimulant, antioxidant, antispasmodic, hypotensive, hepatoprotective, antimicrobial, anticarcinogenic, anticancer, anticytotoxic, antiobesity, anthelmintic, and antagonistic effects.

Gastrointestinal system: Carminative, antispasmodic, digestive enzyme stimulant, bile-promoting. Primary area of traditional use and the most clinically studied domain to date.
Respiratory system: Expectorant, historically used for asthma, bronchitis, and whooping cough.
Cardiovascular system: Preclinical antihypertensive and possible antiplatelet (blood-thinning) effects.
Endocrine/metabolic system: Preclinical antidiabetic effects, possible glucokinase activation and α-glucosidase inhibition.
Nervous system: Preclinical neuroprotective and memory-enhancing effects; sedative properties described historically.
Immune/anti-infective system: Broad-spectrum antimicrobial, antifungal, and antiviral activities demonstrated in vitro.
Oncological: In vitro cytotoxic and chemopreventive activities; no clinical evidence.
Reproductive/gynecological: Traditional use for treatment of problems such as unwanted abortion, unusual pain, sterility, difficult and excessive menstruation, and leucorrhoea.

7. Dosage Forms and Reported Dosages

At this time there is not enough scientific information to determine an appropriate range of doses for asafoetida.

The following dosages are drawn directly from published research:

Functional dyspepsia RCT (Mala et al., 2018): Hard-shell capsules (250 mg × 2/day) of a food-grade formulation of asafoetida (Asafin) for 30 days.
Antidiabetic animal study: Treatment groups in a streptozotocin-induced rat model included asafoetida at 50 mg/kg body weight.
Antihypertensive animal study: Three doses of aqueous extract of asafoetida (10, 30, and 60 mg/kg) were tested in anesthetized rats with angiotensin II–induced hypertension.
Clinical trial safety (Mala et al., 2018): Modern human clinical trials using encapsulated, food-grade asafoetida formulations (e.g., 250 mg twice daily for 30 days) reported no significant adverse effects, hematological changes, or liver/kidney toxicity.
Animal acute toxicity: Animal studies indicate high acute toxicity thresholds (LD50 >4 g/kg), suggesting a wide safety margin, but sub-acute toxicity can occur with chronic, high-dose use.

Culinary use involves far smaller amounts, typically a pinch (50–200 mg of powder) added to hot oil during cooking.

8. Safety Considerations and Drug Interactions

8.1 General Adult Safety

Asafoetida is likely safe for most people in the amounts typically found in foods. There is some evidence that asafoetida is possibly safe when taken by mouth as medicine. It might cause swelling of the lips, burping, intestinal gas, diarrhea, headache, convulsions, blood disorders, and other side effects. The intake of larger dosages can lead to swelling of the lips, digestive complaints such as flatulence and diarrhea, discomfort, and headache.

8.2 Pregnancy and Lactation

It is unsafe to take asafoetida by mouth if pregnant. It might cause a miscarriage. Asafetida has been used traditionally as an emmenagogue and abortifacient. Ethanolic extracts of F. assa-foetida were used in an experiment to determine the (non-estrogen-related) effect on pregnant rats. Pregnancy interceptive activities were established for the extract, possibly caused by interference in the energy metabolism of the uterus.

It is unsafe to take asafoetida by mouth if breastfeeding. The chemicals in asafoetida could pass into breast milk and cause blood disorders in the nursing infant.

8.3 Infants and Children

One case report described the development of severe methemoglobinemia in a 5-week-old child following ingestion of an undetermined quantity of glycerated asafetida solution (a mixture of asafetida, glycerol, propylene glycol, and calcium carbonate). In vitro testing has found that asafetida gum exerts a strong oxidative effect on purified fetal hemoglobin, leading to the conclusion that this folk remedy be considered potentially life-threatening to infants.

Localized eczematous lesions were observed on the abdomens of 32 very young infants (1 to 6 months of age) after topical application of asafetida oleo-gum-resin essential oil to the abdominal area.

8.4 Anticoagulant Drug Interactions

Several coumarin derivatives have been isolated from asafetida resin, suggesting the possibility for potentiation of pharmacologic activity of anticoagulant drugs (e.g., warfarin). Published reports of such interactions are lacking, and the clinical importance of such effects is unknown.

8.5 Antihypertensive Drug Interactions

Based on the documented preclinical antihypertensive mechanism via angiotensin II type 1 receptor antagonism, a part of the antihypertensive effect of asafoetida is mediated through inhibition of the angiotensin II type 1 receptor. The theoretical possibility of additive blood pressure lowering with antihypertensive medications is not yet supported by clinical interaction data.

8.6 Comprehensive Toxicology

To date, there is no comprehensive toxicological study of asafoetida. The lack of standardized asafoetida extracts leads to variable concentrations of bioactive compounds, thereby limiting reproducibility, comparability, and clinical translation of research findings.

References

Health Conditions

Health conditions that Asafoetida may help support.

No conditions available.

Body Systems

Body systems that Asafoetida may help support.

No body systems available.